Genetic signature of vulnerability to inhibitors of base excision repair (BER) in cancer
AssigneesDignity Health, The Translational Genomics Research Institute
InventorsShwetal V. Mehta, Michael E. Berens, Harshil Dineshkumar Dhruv
Life of this patent
Estimating the term…
Abstract
The invention relates to the identification of genetic signatures and expression profiles that are a part of the Base Excision Repair (BER) pathway, a major DNA repair pathway that modifies base lesions. In one embodiment, the present invention provides a method of determining responsiveness of treatment by BER inhibitors for malignant glioma by determining the presence of a low level of expression of Apex 1, a low level of expression of Apex 2, and a high level of expression of MPG.
Claims3
A method of treating glioblastoma in a subject, the method comprising the steps of:
- (a) assaying in a sample from the subject levels of Apex 1, Apex 2, and MPG, relative to non-cancerous cells;
- and
- (b) administering to the subject therapeutically effective amounts of methoxyamine and at least one DNA-damaging agent selected from the group consisting of radiation and temozolomide only if the results of step (a) indicate that the subject has reduced levels of Apex 1 and Apex 2 and increased levels of MPG, relative to non-cancerous cells;
- and
- (c) wherein reduced levels of Apex 1 are less than 3.600, the reduced levels of Apex 2 less than 0.400, and the increased levels of MPG are greater than 1.200.
Dependencies are inferred from the claim text.